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Abstract: Efforts to improve the oral bioavailability of cyclosporine A (CyA) remains a 
challenge in the field of drug delivery. In this study, glyceryl monooleate (GMO)/poloxamer 
407 cubic nanoparticles were evaluated as potential vehicles to improve the oral bioavailability 
of CyA. Cubic nanoparticles were prepared via the fragmentation of a bulk GMO/poloxamer 
407 cubic phase gel by sonication and homogenization. The cubic inner structure formed was 
verified using Cryo-TEM. The mean diameters of the nanoparticles were about 180 nm, and 
the entrapment efficiency of these particles for CyA was over 85%. The in vitro release of CyA 
from these nanoparticles was less than 5% at 12 h. The results of a pharmacokinetic study in 
beagle dogs showed improved absorption of CyA from cubic nanoparticles as compared to 
microemulsion-based Neoral®; higher Cmax (1371.18 ± 37.34 vs 969.68 ± 176.3 ng mL-1), higher 
AUC0–t (7757.21 ± 1093.64 vs 4739.52 ± 806.30 ng h mL-1) and AUC0–∞ (9004.77 ± 1090.38 vs 
5462.31 ± 930.76 ng h mL-1). The relative oral bioavailability of CyA cubic nanoparticles 
calculated on the basis of AUC0–∞ was about 178% as compared to Neoral®. The enhanced 
bioavailability of CyA is likely due to facilitated absorption by cubic nanoparticles rather 
than improved release.
Keywords: nanoparticles, cubosomes, cyclosporine A, glyceryl monooleate, oral drug delivery, 
bioavailability, beagle dogs
Introduction
Cyclosporine A (CyA) is a potent cyclic polypeptide immunosuppressant and has 
been used clinically to prevent allograft rejection in various organ transplantations 
and to treat systemic and local autoimmune disorders.1 Although CyA is clinically 
successful, its oral absorption remains limited due to its high lipophilicity, low intes-
tinal permeability,2 P-glycoprotein (P-gp) efflux from the enterocytes and extensive 
pre-systemic metabolism in the gut wall and liver.3 CyA was originally formulated 
as an oily solution (Sandimmun®), but was found to have high variability in its oral 
bioavailability of between 1% and 89%.4,5 The first-class dosage form of CyA that 
is now used clinically is a self-microemulsifying concentrate (Neoral®) that shows a 
70% to 135% increase in Cmax and AUC in volunteers6 as compared to the oily solution. 
Efforts are still being made to improve the oral bioavailability of CyA to optimize its 
in vivo performance.
To date, comparable or increased bioavailability of CyA as compared to Neoral® 
has been achieved by using a series of vehicles including pH-sensitive nanoparticles,7–9 International Journal of Nanomedicine 2010:5 14
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poly (lactic acid-co-glycolic acid) (PLGA) nanoparticles,10 
positively charged chitosan and gelatin nanoparticles,11 solid 
lipid nanoparticles,12 polymeric micelles,13 sodium cholate/
lecithin mixed micelles,14 sodium lauryl sulfate-dextrin based 
solid microspheres,15 liposomes16 and proliposomes,17 solid 
dispersion containing polyoxyethylene (40) stearate,18 arti-
ficial oil bodies stabilized by caleosi19 and O/W-emulsion.20 
Unfortunately, by simply enhancing the dissolution of 
CyA from the vehicles may not lead to increased oral 
bioavailability of CyA.18 Therefore, new vehicles are required 
to improve dissolution and permeation simultaneously to 
improve oral bioavailability of CyA. Lyotropic vehicles based 
on lipids are able to maintain drugs in a solubilized state in the 
gastrointestinal (GI) tract and penetrate the “unstirred water 
layer” with ease.21 Most importantly, lipid-based drug deliv-
ery systems are able to transform into important secondary 
vehicles (mixed micelles, cubic and hexagonal nanoparticles, 
vesicular carriers) in the GI and are believed to facilitate 
absorption of lipids and poorly water-soluble drugs.22
Cubic nanoparticles (cubosomes) are dispersions of 
cubic phases composed of lipid bilayers partitioning into 
bicontinuous contortions of inter-connecting hydrophilic and 
hydrophobic domains.23,24 The unique structure and properties 
of cubic nanoparticles endowed them with special interest 
as drug delivery carriers.25,26 However, their potential as oral 
drug delivery vehicles has not been extensively explored. 
Preliminary results showed enhanced oral absorption of 
insulin by glyceryl monooleate (GMO)/poloxamer 407 
cubic nanoparticles.27,28 To date, cubic nanoparticles have not 
been well studied for oral delivery of poorly water-soluble 
drugs. Being largely different in physicochemical properties, 
poorly water-soluble drugs in cubic nanoparticles will have 
different fate in the GI tract from water-soluble drugs like 
insulin. For the following reasons, cubic nanoparticles seem 
to be advantageous as oral delivery carriers for poorly water-
soluble drugs. Firstly, being lyotropic,23,24 cubic nanoparticles 
can hold poorly water-soluble drugs in their lipid bilayers in 
a solubilized state. Most importantly, since the cubic phase 
is isotropic, the solubilized state can be retained, without 
concern of drug precipitation in the GI tract, after cubic 
nanoparticles have been broken down into smaller par-
ticles during the digestion process by the intestinal lipases. 
Secondly, the cubic nanoparticles are bioadhesive,26 which 
increases the opportunities of close contact of drug-loaded 
nanoparticles with intestinal cell membrane. Thirdly, as a 
secondary vehicle during lipid digestion, cubic nanoparticles 
are assumed to play important roles in the process of lipid and 
drug absorption.22 Since permeation enhancement by cubic 
phases has been observed for transdermal and transmucosal 
delivery,25,26 similar mechanisms may be proposed for cubic 
nanoparticles as oral delivery carriers.
In a previous study,29 enhanced oral bioavailability of 
simvastatin, a BCS II drug, has been achieved by GMO/
poloxamer 407 cubic nanoparticles. Taking advantage of 
their permeation-enhancing effect, cubic nanoparticles were 
evaluated as potential vehicles to improve the oral bioavail-
ability of CyA, a more challenging BCS IV drug of poor 
water-solubility and poor permeability.
Materials and methods
Materials
Cyclosporine A (CyA) was purchased from Pharmaceuti-
cal Factory of Sichuan Institute of Antibiotic Industries 
(Chengdu, China). Glyceryl monooleate (monoolein, GMO) 
DIMONANR MO 90/D was a gift from Danisco Cultor 
(Grindsted, Denmark). Poloxamer 407 (PEO98POP67PEO98) 
was provided by BASF (Ludwigshafen, Germany). Sephadex 
G-50 was purchased from Pharmacia. Water was prepared by 
Millipore purifying system (Molsheim, France). HPLC-grade 
methanol was supplied by Merck (Darmstadt, Germany). All 
other chemicals used in the study were of analytical grade.
Preparation of cyA-loaded gMO/
poloxamer 407 cubic nanoparticles
Cubic nanoparticles were prepared through the fragmentation 
of GMO/poloxamer 407 bulk cubic gel.30 GMO (500 mg) and 
poloxamer 407 in various weight (40-100 mg) were firstly 
melted at 60°C in a hot water bath, after which CyA was 
added and stirred continuously to dissolve. Milli-Q deionized 
water (250 µL) was added gradually and vortex mixed to 
achieve a homogenous state. After equilibration for 48 h 
at room temperature, an optically isotropic cubic phase gel 
formed. After addition of 10 mL deionized water, the cubic 
gel was first disrupted by mechanical stirring. The crude 
dispersion was subsequently fragmented by intermittent 
probe sonication at 200 W energy input (JYD-650, Shanghai, 
China) under cooling in a 20°C water bath for 10 min, and 
homogenized by passing five cycles through a high-pressure 
homogenizer (Avestin Em-C3, Ottawa, Canada) at 670 bar 
and 25°C to obtain an opalescent dispersion of the cubic 
nanoparticles. The final dispersions of cubic nanoparticles 
were stored at room temperature until required.
For preparation of samples for release and pharma-
cokinetic studies, the crude dispersions of tens of repeats 
were pooled and further processed under the conditions 
described above to obtain the fine dispersion of CyA-loaded International Journal of Nanomedicine 2010:5 15
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GMO/poloxamer 407 cubic nanoparticles. The free drug was 
removed by eluting through a Sephadex G-50 column fol-
lowing the procedures similar to those described below for 
the determination of entrapment efficiency. The formulation 
details and fundamental properties of the cubic nanoparticle 
dispersion were listed in Table 1.
characterization of cyA-gMO/
poloxamer 407 cubic nanoparticles
The inner cubic structure of the nanoparticles was character-
ized by Cryo-TEM (JOEL JEM-2010, Tokyo, Japan). A thin 
liquid film of nanoparticles (20-400 nm) was prepared on 
a copper grid and then immersed into liquid ethane. Excess 
ethane was removed, and the sample was transferred into a 
Cryo-TEM. Samples were viewed under low-dose condi-
tions at a constant temperature of -170°C. All images were 
recorded digitally with a CCD camera (Gatan 832) under 
low-dose conditions with an underfocus of approximately 
3 µm and acceleration voltage of 120 kV .
Particle size was determined by photon correlation spec-
troscopy using a Zetasizer Nano® (Malvern Instruments, 
Malvern, UK) equipped with a 4 mW He–Ne laser (633 nm) 
at 25°C. Samples were diluted with deionized water prior 
to measurement, setting dispersant viscosity to 0.8872 cP 
at 25°C.
For determination of entrapment efficiency, it was man-
dated to separate free CyA from nanoparticle-associated 
CyA. Gel permeation chromatography was one of such 
separating method commonly used.31,32 In this study, the 
entrapment efficiency of CyA was measured by gel perme-
ation chromatography using Sephadex G-50. CyA-loaded 
cubic nanoparticles were eluted through Sephadex G-50 
(2 g) columns (φ1.5 cm × 30 cm) after preconditioning with 
30 mL water. Cubic nanoparticles were separated from free 
CyA by monitoring turbidity at a wavelength of 500 nm by 
a UV-2401 spectrophotometer (Shimadzu, Tokyo, Japan). 
Good column recoveries of 98%-101% were observed. Free 
and associated CyA were determined by HPLC at 226 nm. 
The LC-10ATvp HPLC system (Shimadzu) was composed 
of a binary pump, a tunable ultraviolet detector, a column 
heater and a manual injector. The mobile phase, pumped 
at a flow rate of 1.0 mL min-1, consisted of an acetonitrile/
water/tert-butylmethylether/phosphoric acid (600/350/50/1, 
v/v/v/v) mixture. CyA was separated using a C18 column 
(Venusil XBP, 5 µm, 4.6 mm × 150 mm; Agela, Tianjin, China) 
guarded with a refillable precolumn (C18, 2.0 mm × 20 mm; 
Alltech, Lexington, KY, USA) and a stainless pre-heating tube 
1000 mm in length with an internal diameter of 0.25 mm main-
tained at 70°C. The linearity range of the calibration curve 
was within 1.0-15 µg mL-1 with a correlation coefficient of 
0.9997 ± 0.0002. Entrapment efficiency (EE%) was calculated 
as Wc/Wt × 100%, where Wc and Wt denote CyA content in 
cubic nanoparticles and total drug in dispersion.
Release of cyA from cubic nanoparticles
A preliminary study on CyA release from the cubic 
nanoparticles of the same formulation as for the further phar-
macokinetic study (Table 1) was carried out using the dynamic 
dialysis method in a ZRS-8G release tester (Tianjin, China). 
Two milliliters CyA-loaded cubic nanoparticles (4 mg CyA 
equivalent) were sealed in dialysis bags (14000 MWCO, Mil-
lipore, Boston, MA, USA) and immersed in 100 mL aqueous 
medium containing 0.2% (w/v) sodium lauryl sulfate (SDS) 
thermostatically maintained at 37 ± 0.5°C and stirred at a revo-
lution speed of 100 rpm. At time intervals of 0.25, 0.50, 0.75, 
1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10, and 12 h, 0.2 mL of medium 
was withdrawn and filter through a 0.45 µm nylon film. The 
CyA content was then determined by HPLC as described 
above. Since the solubility of CyA in 0.2% SDS solution 
was about 0.921 mg/mL, the sink conditions were maintained 
throughout the release test. Nearly complete release within 1 h 
was observed for saturated CyA solution indicating negligible 
hindering effect of the dialysis bag on CyA release.
Determination of cyA in dog whole 
blood by RP-hPLc
CyA in dog whole blood was determined using our HPLC-
UV method as described above with minor modification. 
The same LC-10ATvp HPLC system and Venusil XBP 
C18 column with guard column and pre-heating assem-
blies as in entrapment efficiency determination was used. 
The mobile phase was composed of acetonitrile/water/
Table 1 Formulation details and properties of cyA-loaded cubic nanoparticles
Poloxamer 407/ 
GMO ratio
Theoretical solid 
content (%, w/v)a
Theoretical drug 
loading (%)b
Particle 
size (nm)
Polydispersity  Entrapment 
efficiency (%)
12/100 11.4 1.75 136.4 ± 5.8 0.291 91.45 ± 1.45
Notes: acalculated as the weight ratio of (gMO + poloxamer 407) to total sample (gMO + poloxamer 407 + water); bcalculated as the weight ratio of cyA to total solids 
(cyA + gMO + poloxamer 407).International Journal of Nanomedicine 2010:5 16
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tert-butylmethylether/phosphoric acid (525/425/50/1, 
v/v/v/v) and run at a flow rate of 1.5 mL min-1. CyA was 
measured at 210 nm.
To prepare dog blood samples, CyA was extracted by the 
reported liquid-liquid extraction procedures7,33 with minor 
modification. To 2 mL dog blood, add 100 mg of sodium 
fluoride followed by 160 µL of internal standard solution 
(cyclosporine D, 10 µg mL-1 in methanol). After vortex 
mixing for 30 s, 5 mL of diethyl ether anhydrous was added 
and vortex mixed for 10 min. After centrifuging at 2000 × g 
for 10 min, the organic layer was transferred to another tube 
and evaporated under a light stream of nitrogen at 40°C. The 
residue was reconstituted using 120 µL methanol/0.05 mol L-1 
hydrochloric acid solution (6/4, v/v). After washing the injec-
tion solution with 1 mL n-hexane for 2 min and a brief 
centrifugation at 2000 × g for 10 min, 20 µL of the injection 
solution was injected for HPLC analysis. Quantification 
was based on the peak area ratio R (ACyA/AIS). Linearity was 
observed over the concentration range of 25-2000 ng mL-1 
with correlation coefficients of over 0.99 (a typical calibra-
tion curve: R = 0.003C-0.0842, (r = 0.9976, n = 7). The 
lower limit of quantification (LLOQ) for the determination of 
CyA in dog plasma was found to be 12.1 ng mL-1. Accuracy 
for the determination of CyA in dog plasma (n = 9) was 
94.58 ± 3.06%. Intra-day and inter-day precisions were 
below 7% and the extraction recovery of CyA in dog plasma 
(n = 9) was 74.36 ± 3.44%.
Bioavailability study
The pharmacokinetics of the CyA cubic nanoparticle 
dispersion (Table 1) was compared with a CyA capsule 
(25 mg/capsule, Sandimmun Neoral®, Novartis) in beagle 
dogs in a randomized two-period crossover study after an oral 
dose of 100 mg equivalent CyA. The particle size of Neoral® 
was 14.3 ± 4.52 nm determined by Zetasizer Nano® under 
conditions in this study after diluting its content with 25 mL 
deionized water. The washout period between administra-
tions was one week. Six male beagle dogs weighing 8-10 kg 
were kept in an environmentally controlled breeding room 
(22 ± 2°C, 60 ± 5% relative humidity, fresh air circulating) 
for one week before the start of the experiment. The dogs 
were fed standard laboratory chow with water and fasted 
overnight before the experiment. Guidelines on experi-
ments involving use of animals were issued by the Ethical 
Committee of Fudan University in adherence to MOH 
guidelines  (Ministry of Health of the People’s Republic of 
China Publication, 1998). The cubic nanoparticle dispersion 
was gavage administered, whereas the Neoral capsules were 
put at the pharyngeal site and swallowed spontaneously by 
the animals, followed by flushing with 20 mL of water. After 
administration, about 4 mL of blood was collected through the 
hind leg vein into heparinized tubes at time intervals of 0.5, 
1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, and 24.0 h. Blood 
samples were stored at -20°C until analysis.
Pharmacokinetic analysis was performed by a model-
independent method and a two-compartmental method, 
respectively, using the 3P87 computer program (issued by the 
State Food and Drug Administration of China for pharmaco-
kinetic study). Cmax and Tmax were observed as raw data. Area 
under the curve to the last measurable concentration (AUC0−t) 
was calculated by the linear trapezoidal rule. Area under 
the curve extrapolated to infinity (AUC0−∞) was calculated 
as AUC0−t + Ct/k, where Ct and k were the last measurable 
concentration and the elimination constant, respectively.
statistical analysis
Raw data were analyzed using the SPSS statistical software 
(version 11.0, SPSS, Inc., Chicago, IL, USA). Post-hoc 
multiple comparisons were done using one-way ANOVA 
and the Student–Newman–Keuls test (q test) to determine 
the significance of differences between groups; a P value less 
than 0.05 was considered statistically significant.
Results and discussion
Preparation and characterization of cyA-
gMO/poloxamer 407 cubic nanoparticles
Clear and viscous gels were formed using the GMO/
poloxamer 407 binary systems with a GMO/poloxamer 407 
ratio of 500 mg/40 mg (7.4%, w/w, poloxamer 407 weight 
percentage) to 500 mg/100 mg (16.7%, w/w). Analysis of 
each preparation using polarized light microscopy indicated 
that the diffraction of a dark isotropy indicated the forma-
tion of the liquid crystalline phase. At lower CyA loading, 
no significant change in the appearance of the bulk gel was 
observed. However, when the theoretical CyA loading 
increased to over 2% (w/w), calculated as the ratio of CyA to 
total solids, the bulk gel began to turn opalescent indicating 
reduced solubility of CyA in the GMO/poloxamer 407 cubic 
phase. The theoretical CyA loading was fixed at 1.75% in 
all preliminary studies.
Cryo-TEM revealed the inner structure of the blank 
(Figure 1A) and CyA-loaded (Figure 1B) GMO/poloxamer 
407 cubic nanoparticles, whose formulation details and 
properties are listed in Table 1. Typical cubic structures indi-
cating the formation of cubic nanoparticles were confirmed; 
nanoparticles of larger diameters had bulk cubic geometry, International Journal of Nanomedicine 2010:5 17
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while those of smaller diameters showed oval or spherical 
geometry. CyA loading at 1.75% (w/w) seemed to have little 
effect on the cubic structure of the nanoparticles.
During the sonication procedure, the cubic phase gel 
was efficiently disrupted. Particle size analysis gave a mean 
diameter of 200-300 nm and a wide particle size distribution 
ranging from 30 nm to 1000 nm (Figure 2A). After homog-
enization, the mean diameter of the particles was reduced to 
about 180 nm with a narrower lognormal size distribution 
within 70-300 nm (Figure 2B). The GMO/poloxamer 407 
ratio had no significant effect (P  0.05) on the particle size 
except at the ratio of 100/20 (Figure 3A). Increasing the 
homogenization pressure to 670 bar could efficiently reduce 
the particle size (Figure 3B) as a result of increased energy 
input, whereas the homogenization cycles, either three or five, 
appeared to have no significant effect on particle size except 
at 350 bar (Figure 3B). It seems that homogenization was 
more efficient at higher pressure and three homogenization 
cycles were enough to obtain stable particle size, while at 
lower pressures more homogenization cycles were needed to 
obtain cubic nanoparticles of smaller diameters. Under the 
homogenization conditions in this study, cubic nanoparticles 
with reproducible particle size and distribution could be 
obtained.
The entrapment efficiency of CyA into cubic nanopar-
ticles was found to be exclusively high for all formulations 
although the formulation variables and processing conditions 
had definite influence on entrapment efficiency. Under dif-
ferent GMO/poloxamer 407 ratios, the entrapment efficiency 
was between 86.2%-92.4% and showed minimal loss into 
the dispersion medium (Figure 4A). Highest entrapment 
efficiency was achieved at GMO/poloxamer 407 ratio of 
100/9, which was significantly different from those obtained 
at other GMO/poloxamer 407 ratios (P  0.05). At GMO/
poloxamer 407 ratios of 100/15 and 100/20, the entrapment 
efficiencies were similar and significantly lower than those 
obtained at other GMO/poloxamer 407 ratios (P  0.05). 
Poloxamer 407 seemed to facilitate solubilization of CyA in 
GMO/poloxamer 407 cubic structure at lower levels, which 
reached a peak at GMO/poloxamer 407 ratio of 100/9. How-
ever, when the content of poloxamer 407 increased to much 
high level, the ability of the cubic structure to hold CyA 
decreased possibly due to the increased hydrophilicity of the 
cubic structure and escape of CyA into the outer aqueous 
environment together with poloxamer 407. Homogenization 
pressure and cycles appeared to have no significant effect 
on entrapment efficiency except that significant difference 
(P  0.05) was observed for three and five homogenization 
cycles at 670 bar (Figure 4B). The high entrapment efficiency 
may be ascribed to the high hydrophobicity of CyA and its 
relatively large molecule size.
The high affinity of CyA with the hydrophobic domain 
in the cubic phase made it difficult to be released from the 
nanoparticles. As a result, the overall release of CyA from 
cubic nanoparticles was less than 5% at 12 h (Figure 5). 
Similarly, release of CyA from microemulsion (Sandimmun 
Neoral®) was less than 5% at 12 h too. Since the overall 
release of CyA from cubic nanoparticles was negligible, we 
did not take out extensive study on release of other formula-
tions in this study.
Pharmacokinetics and oral 
bioavailability
The oral bioavailability of CyA from cubic nanoparticle was 
assessed in beagle dogs and compared to Sandimmun Neoral®. 
Figure 6 shows the mean CyA plasma concentration versus 
time plots of the two CyA formulations. The pharmacokinetic 
parameters obtained using the noncompartmental method and 
two-compartmental method are given in Table 2 and 3.
Figure 1 cryo-TeM photographs of blank A) and cyA-loaded B) cubic nanoparticles. 
The bars equal 200 nm.International Journal of Nanomedicine 2010:5 18
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The noncompartmental calculation indicated that 
the Tmax of cubic nanoparticles (2.42 ± 0.80 h) appeared 
to be longer than that for Neoral® (2.00 ± 0.71 h) but, 
was not significantly different (P  0.05). However, 
the Cmax of cubic nanoparticles (1371.18 ± 357.34 ng 
mL-1) was significantly different from that of Neoral® 
(969.68 ± 176.3 ng mL-1) (P  0.05). Cubic nanoparticles had 
a faster elimination rate with a smaller t1/2 (12.14 ± 8.37 h) 
than Neoral® (22.29 ± 10.54 h) (P  0.05). Both the AUC0–t 
(7757.21 ± 1093.64 vs 4739.52 ± 806.30 ng h mL-1) and 
AUC0−∞ (9004.77 ± 1090.38 vs 5462.31 ± 930.76 ng h mL-1) 
were significantly different when comparing the two for-
mulations (P  0.05). Indeed, calculated on the basis of 
the AUC0−∞ of each formulation, the oral bioavailability of 
CyA-loaded GMO/poloxamer 407 cubic nanoparticles was 
about 178% as compared to Sandimmun Neoral®.
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A two-compartmental model can be employed to fit the 
experimental data of both CyA cubic nanoparticles and 
Sandimmun Neoral® with regression coefficients of 0.9747 
and 0.9901, respectively. The absorption rates of the two 
formulations were similar with t1/2(a) of 1.46 ± 0.37 h and 
1.14  ±  0.61 h for cubic nanoparticles and Neoral®, respectively. 
The elimination from the central compartment (k10) showed 
no significant difference (P  0.05), while transportation 
from the central to the peripheral compartment (k12) of 
cubic nanoparticles was faster than Neoral® (P  0.05). No 
significant differences were observed for the transportation 
of CyA from peripheral to the central compartment (k21) 
(P  0.05). Distribution (t1/2(α)) of CyA after cubic nanopar-
ticles administration was slower than Neoral® (P  0.05) 
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although the overall elimination of CyA cubic nanoparticles 
was faster. Indeed, plasma CyA was maintained at a high level 
for a longer period as compared to Neoral®. This observa-
tion may be ascribable to the enhanced absorption of CyA 
from cubic nanoparticles. The pharmacokinetic parameters 
of Neoral® reported in this study differ from that reported by 
Guo and colleagues16 possibly due to the fact that we are using 
a beagle dog model rather than a rabbit model. The results in 
this study showed smaller α, β, Ka, K10, K12 and K21 values and 
larger T1/2(a), T1/2(α) and T1/2(β) values, indicating slower absorp-
tion, distribution, transportation between compartments and 
elimination in beagle dogs than in rabbits.
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Figure 5 Release profiles of CyA-loaded GMO/poloxamer 407 cubic nanoparticles and Neoral® capsules (n = 3).
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Figure 6 Beagle dog plasma cyA concentrations versus time plot after a single oral dose of 100 mg equivalent cyA cubic nanoparticles or sandimmun Neoral® (n = 6).
Table 2 Pharmacokinetic parameters after oral administration of cyA-loaded cubic nanoparticles and sandimmun Neoral® calculated 
by a noncompartmental method
Formulation tmax (h) Cmax (ng mL-1) t1/2 (h) AUC0–t  
(ng h mL-1)
AUC0–∞  
(ng h mL-1)
MRT (h)  Relative 
bioavailability (%)*
cubic 
nanoparticles
2.42 ± 0.80 1371.18 ± 357.34 12.14 ± 8.37 7757.21 ± 1093.64 9004.77 ± 1090.38 6.56 ± 1.08 177.92 ± 47.68
sandimmun 
Neoral®
1.83 ± 0.75 969.68 ± 176.30 22.29 ± 10.54 4739.52 ± 806.30 5462.31 ± 990.76 6.39 ± 0.70  
Note: *calculated on AUC0–∞ with sandimmun Neoral® as reference.International Journal of Nanomedicine 2010:5 22
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Table 3 Pharmacokinetic parameters after oral administration of cyA-loaded cubic nanoparticles and sandimmun Neoral® calculated 
by a two-compartmental method
Formulation ka (h-1) α (h-1) β (h-1) t1/2(α) (h) t1/2(β ) (h) t1/2(a) (h) k10 (h-1) k12 (h-1) k21 (h-1)
cubic 
nanoparticles
0.52 ± 0.076 0.24 ± 0.068 0.062 ± 0.056 3.05 ± 0.90 12.14 ± 8.37 1.46 ± 0.37 0.096 ± 0.047 0.081 ± 0.10 0.13 ± 0.10
sandimmun 
Neoral®
0.73 ± 0.37 0.41 ± 0.12 0.032 ± 0.022 1.84 ± 0.57 22.29 ± 10.54 1.14 ± 0.61 0.10 ± 0.054 0.19 ± 0.10 0.14 ± 0.17
Comparing the pharmacokinetic parameters and 
oral bioavailability data indicates the effects of cubic 
nanoparticles on the oral absorption of CyA. Although the 
significance of the cubic structure of the nanoparticles on 
enhanced absorption has not been elucidated at this stage 
of study, there are a few assumptions regarding the merits 
of cubic nanoparticles as potential oral drug delivery car-
riers. Studies by Um and colleagues28 confirmed that both 
released drugs or cubic nanoparticle-associated drugs can be 
transported across the endothelial cell membranes enhanc-
ing drug absorption. Whether or not cubic nanoparticles can 
be transported intact across cell membranes has yet to be 
determined however, they are known to possess lyotropic 
properties. This property makes it easier for nanoparticles 
to penetrate the “unstirred water layer”21,34,35 and make 
closer contact with cell membranes. This may promote their 
uptake by endothelial membranes although this has yet to be 
tested experimentally. It has to be stressed however, that the 
transportation of cubic nanoparticles across cell membranes 
is not the only mechanism by which they may improve 
drug absorption as compared to orally administered lipid 
carriers. In previous studies with GMO liquid-crystalline 
phase oral formulation, digestion of the matrix by intestinal 
esterase to form lyotropic nanostructures was proposed as 
the main mechanism to enhance the oral bioavailability of 
the incorporated drugs.36 Oleyl glycerate (OG) matrices 
showed slower digestion rate than GMO, which was 
attributable to the significant enhancement in oral bioavail-
ability and extended absorption profile for a few days.37 It 
can also be assumed that cubic nanoparticles will also be 
digested in the GI and broken down into smaller nanopar-
ticles or drug-associated micelles. One advantage of cubic 
nanoparticles is that they are isotropic and fragmentation 
only results in the formation of smaller cubic nanoparticles 
that retain the properties of their “parental” nanoparticles. 
Here, the secondary cubic nanoparticles or derivative 
vehicles like micelles may facilitate further contact with 
cell membrane and facilitate absorption. Recent work on 
liquid crystalline matrix based on phytantriol indicated 
that the nanostructure of these materials might provide the 
ability to tailor the release rate and oral absorption kinetics 
of hydrophilic drugs.38
It seems that multiple mechanisms, rather than a single 
mechanism, including transportation of cubic nanopar-
ticles across cell membranes, enhanced contact with cell 
surfaces and enhanced absorption through the lipid digestion 
process may contribute to enhanced oral bioavailability of CyA.
Conclusions
The results of this study indicated that cubic nanoparticles 
were superior to microemulsion-based formulation in improv-
ing the oral bioavailability of CyA. The oral bioavailability 
of CyA cubic nanoparticles were enhanced significantly to 
approximately 178% as compared to Sandimmun Neoral®.
Acknowledgments
This work was supported by National Key Basic Research 
Program of China (2007CB935800, 2009CB930300) and 
partly by the Ministry of Education (200802461092). We 
thank Dr Kunpeng Li of Zhongshan University for help with 
Cryo-TEM analysis and Dr Jianming Chen of the Second 
Military Medical University for help with particle size 
measurements. The authors report no conflicts of interest 
in this work.
References
  1.  Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review 
of the pharmacokinetic properties, clinical efficacy and tolerability of a 
microemulsion-based formulation (Neoral®) in organ transplantation. 
Drugs. 2001;61:1957–2016.
  2.  Hebert MF. Contributions of hepatic and intestinal matabolism and 
Pglycoprotein to cyclosporin ans tacrolimus oral drug delivery. Adv 
Drug Deliv Rev. 1997;27:201–214.
  3.  Tjai JF, Webber IR, Back DJ. Cyclosporin metabolism by the gastroin-
testinal mucosa. Br J Clin Pharmacol. 1991;31:344–346.
  4.  Noble S, Markham A. Cyclosporin: a review of the pharmacokinetic 
properties, clinical efficacy and tolerability of a microemulsion-based 
formulation (Neoral®). Drugs. 1995;50:924–941.
  5.  Vonderscher J, Meinzer A. Rationale for the development of Sandimmun 
Neoral. Transplant Proc. 1994;26:2925–2927.
  6.  Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity 
of cyclosporine pharmacokinetics from a microemulsion formulation. 
Pharm Res. 1994;11:301–304.
  7.  Dai J, Nagai T, Wang X, et al. pH-sensitive nanoparticles for improving 
the oral bioavailability of cyclosporine A. Int J Pharm. 2004;280: 
229–240.International Journal of Nanomedicine 2010:5
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
23
Oral bioavailability of cyclosporine A Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
  8.  Wang XQ, Dai JD, Chen Z, et al. Bioavailability and pharmacokinetics 
of cyclosporine A-loaded pH-sensitive nanoparticles for oral 
administration. J Control Release. 2004;97:421–429.
  9.  Wang XQ, Huang J, Dai JD, et al. Long-term studies on the stability 
and oral bioavailability of cyclosporine A nanoparticle colloid. Int J 
Pharm. 2006;322:146–153.
10.  Italia JL, Bhatt DK, Bhardwaj V , et al. PLGA nanoparticles for oral 
delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies 
in comparison to Sandimmun Neoral. J Control Release. 2007;119: 
197–206.
11.  El-Shabouri MH. Positively charged nanoparticles for improving the oral 
bioavailability of cyclosporin-A. Int J Pharm. 2002;249:101–108.
12.  Müller RH, Runge S, Ravelli V , et al. Oral bioavailability of cyclospo-
rine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J 
Pharm. 2006;317:82–89.
13.  Aliabadi HM, Brocks DR, Lavasanifar A. Polymeric micelles for the 
solubilization and delivery of cyclosporine A: pharmacokinetics and 
biodistribution. Biomaterials. 2005;26:7251–7259.
14.  Guo J, Wu T, Ping Q, et al. Solubilization and pharmacokinetic behaviors 
of sodium cholate/lecithin-mixed micelles containing cyclosporine A. 
Drug Deliv. 2005;12:35–39.
15.  Lee EJ, Lee SW, Choi HG, et al. Bioavailability of cyclosporin A 
dispersed in sodium lauryl sulfate-dextrin based solid microspheres. 
Int J Pharm. 2001;218:125–131.
16.  Guo J, Ping Q, Chen Y. Pharmacokinetic behavior of cyclosporin A 
in rabbits by oral administration of lecithin vesicle and Sandimmun 
Neoral. Int J Pharm. 2001;216:17–21.
17.  Shah NM, Parikh J, Namdeo A, et al. Preparation, characterization and 
in vivo studies of proliposomes containing Cyclosporine A. J Nanosci 
Nanotechnol. 2006;6:2967–2973.
18.  Liu C, Wu J, Shi B, et al. Enhancing the bioavailability of cyclosporine 
a using solid dispersion containing polyoxyethylene (40) stearate. Drug 
Dev Ind Pharm. 2006;32:115–123.
19.  Chen MC, Wang JL, Tzen JT. Elevating bioavailability of cyclosporine 
a via encapsulation in artificial oil bodies stabilized by caleosin. 
Biotechnol Prog. 2005;21:1297–1301.
20.  Kim SJ, Choi HK, Lee YB. Pharmacokinetic and pharmacodynamic 
evaluation of cyclosporin A O/W-emulsion in rats. Int J Pharm. 
2002;249:149–156.
21.  Thomson AB, Schoeller C, Keelan M, et al. Lipid absorption: passing 
through the unstirred layers, brush-border membrane, and beyond. Can 
J Physiol Pharmacol. 1993;71:531–555.
22.  Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formula-
tions: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug 
Discov. 2007;6:231–248.
23.  Barauskas J, Johnsson M, Tiberg F. Self-aseembled lipid supersture 
beyond vesicles and liposomes. Nano Lett. 2005;5:1615–1619.
24.  Yang D, Armitage B, Marder SR. Cubic liquid-crystalline nanoparticles. 
Angew Chem Int Ed. 2004;43:4402–4409.
25.  Esposito E, Cortesi R, Drechsler M, et al. Cubosome dispersions as 
delivery systems for percutaneous administration of indomethacin. 
Pharm Res. 2005;22:2163–2173.
26.  Garg G, Saraf S, Saraf S. Cubosomes: an overview. Biol Pharm Bull. 
2007;30:350–353.
27.  Chung H, Kim J, Um JY, et al. Self-asembled “nanocubicle” as a carrier 
for peroral insulin delivery. Diabetologia. 2002;45:448–451.
28.  Um JY, Chung H, Kim KS, et al. In vitro cellular interaction and 
absorption of dispersed cubic particles. Int J Pharm. 2003;253: 
71–80.
29.  Lai J, Chen J, Lu Y, et al. Glyceryl monooleate/poloxamer 407 cubic 
nanoparticles as oral drug delivery systems: I. In vitro evaluation 
and enhanced oral bioavailability of the poorly water-soluble drug 
simvastatin. AAPS PharmSciTech. 2009;10:960–966.
30.  Gustafsson J, Ljusberg-Wahren H, Almgren M. Cubic lipid-water phase 
dispersed into submicron particles. Langmuir. 1996;12:4611–4613.
31.  Jin Y, Ai P, Xin R, et al. Morphological transformation of self-assembled 
nanostructures prepared from cholesteryl acyldidanosine and the optimal 
formulation of nanoparticulate system: Effect of solvents, acyl chain 
length and poloxamer 188. J Colloid Interf Sci. 2008;326:275–282.
32.  Missirlis D, Kawamura R, Tirelli N, et al. Doxorubicin encapsulation 
and diffusional release from stable, polymeric, hydrogel nanoparticles. 
Eur J Pharm Sci. 2006;29:120–129.
33.  Chimalakonda AP, Shah RB, Mehvar R. High-performance liquid 
chromatographic analysis of cyclosporin A in rat blood and liver 
using a commercially available internal standard. J Chromatogr B. 
2002;772:107–114.
34.  Katneni K, Charman SA, Porter CJ. An evaluation of the relative roles 
of the unstirred water layer and receptor sink in limiting the in-vitro 
intestinal permeability of drug compounds of varying lipophilicity. 
J Pharm Pharmacol. 2008;60:1311–1319.
35.  Korjamo T, Heikkinen AT, Mönkkönen J. Analysis of unstirred water 
layer in in vitro permeability experiments. J Pharm Sci. 2009;98: 
4469–4479.
36.  Boyd BJ, Whittaker DV , Khoo SM, et al. Lyotropic liquid crystalline 
phases formed from glycerate surfactants as sustained release drug 
delivery systems. Int J Pharm. 2006;309:218–226.
37.  Boyd BJ, Khoo SM, Whittaker DV , et al. A lipid-based liquid crystal-
line matrix that provides sustained release and enhanced oral bioavail-
ability for a model poorly water soluble drug in rats. Int J Pharm. 
2007;340:52–60.
38.  Lee KW, Nguyen TH, Hanley T, et al. Nanostructure of liquid crystalline 
matrix determines in vitro sustained release and in vivo oral absorp-
tion kinetics for hydrophilic model drugs. Int J Pharm. 2009;365: 
190–199.